How will a new pay settlement for NHS staff affect real-terms earnings? A new pay offer aiming to end NHS strikes in England has been accepted by a majority of the unions involved in talks, resulting in likely pay increases for NHS staff other than doctors. What does this settlement mean for NHS staff pay packets compared to salaries in 2010, and where does this leave discussions between government and the NHS workforce? Nuffield Trust
Thursday 4 May 2023
Specialist perinatal mental health care in the UK 2023
Specialist perinatal mental health care in the UK 2023 The MMHA’s latest report on specialist perinatal mental health (PMH) community services in the UK highlights the significant progress made in all four nations since 2013. However, access to life-saving mental healthcare for pregnant women and new mothers remains uneven, with many regions still lacking the necessary resources. Mental health-related deaths during pregnancy or up to six weeks after birth are increasing, emphasising the urgency of addressing this issue. Maternal Mental Health Alliance
See also:
- Left unchecked – why maternal mental health matters (report) Healthwatch
- Maternal mental health: The changes your feedback made possible Healthwatch
- Maternal mental health support continues to improve despite NHS strain Ipsos
- RCPsych urges new and expectant mums to seek help for mental health issues Royal College of Psychiatrists
- New mums missing out on mental health services, report finds BBC News
- Maternal mental health is in crisis and the pandemic has made things worse The Daily Telegraph
- Poor mental health support during pregnancy risks UK women’s lives The Guardian
- NHS must ‘urgently’ publish data on mental health checks for pregnant women, say top doctors The Independent
- Pregnant women ‘suffer in silence for too long’ with mental health issues The Independent
- Pregnant women 'suffer in silence' for too long with mental health issues, say experts Sky News
Waiting for NHS hospital care: the role of the independent sector in delivering orthopaedic and ophthalmic care
Waiting for NHS hospital care: the role of the independent sector in delivering orthopaedic and ophthalmic care The waiting list for planned hospital care – which stood at 7.21 million in January 2023 – has grown by 58% since just before the start of the pandemic. To help expand capacity and address this backlog the NHS has been looking to independent sector providers (ISPs) to treat more NHS patients. The Health Foundation
See also:
- Greater use of private hospitals will have ‘limited impact’ on NHS backlog The Health Foundation
Healthy New Towns four years on: the legacy of a national innovation programme
Healthy New Towns four years on: the legacy of a national innovation programme It’s often said that the NHS is good at trialling new approaches through pilot schemes but less good at locking in the benefits or spreading the learning more widely. The Healthy New Towns programme was part of a flurry of innovation in the years following the publication of the NHS five-year forward view. The King's Fund
Snowballs and eels: a rapid review of national funding for cross-sector partnership building in health and care in England from 2019 to 2022
Snowballs and eels: a rapid review of national funding for cross-sector partnership building in health and care in England from 2019 to 2022 This report considers the results of a rapid review of the national funding available for cross-sector partnership building in health and care over the last three years. Considering the longer term, it finds that since the launch of the 42 sustainability and transformation partnerships in 2016, through to the placing of integrated care systems (ICSs) onto a statutory footing in July 2022, much progress has been made. It concludes that external funding and support for the voluntary and community sector (VCS) continues to have a part in supporting local partnerships to develop and thrive and play a full role in ICSs. National Association for Voluntary and Community Action
Study launched to find out more about mpox immunity
Study launched to find out more about mpox immunity The UK Health Security Agency (UKHSA), supported by the Chelsea and Westminster Hospital NHS Foundation Trust, has launched a study to better understand how the body reacts to the mpox virus and produces antibodies.
People will be invited by the Trust in London to take part in the LIMIT (Longitudinal immunology of mpox virus infection) study, which involves a simple questionnaire and a series of postal antibody tests.
Independent report: COVID-19 vaccination of children aged 6 months to 4 years: JCVI advice, 9 December 2022 (updated 26 April 2023)
Independent report: COVID-19 vaccination of children aged 6 months to 4 years: JCVI advice, 9 December 2022 (updated 26 April 2023) Statement setting out the advice from the Joint Committee on Vaccination and Immunisation (JCVI) on COVID-19 vaccination for children aged 6 months to 4 years. Department of Health and Social Care
New Alzheimer's drug slows disease by a third
New Alzheimer's drug slows disease by a third We could be entering the era of Alzheimer's treatments, after the second drug in under a year has been shown to slow the disease.
Experts said we were now "on the cusp" of drugs being available, something that had recently seemed "impossible".
The company Eli Lilly has reported its drug - donanemab - slows the pace of Alzheimer's by about a third.
However two volunteers, and possibly a third, died as a result of dangerous swelling in the brain. BBC News
See also:
- Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease Eli Lilly
- New Alzheimer’s drug slows cognitive decline by 35%, trial results show The Guardian
- 'The Beginning Of The End' For Alzheimer’s? Experts Hail New Drug Huffington Post UK
- World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’ The Independent
- Alzheimer's: New drug can reduce disease symptoms by up to 35% Sky News
US drug regulator approves world's first RSV vaccine
US drug regulator approves world's first RSV vaccine The US Food and Drug Administration has approved a vaccine against respiratory syncytial virus (RSV) - an illness that kills thousands of Americans each year.
The vaccine still needs approval from the US Centers for Disease Control and Prevention before it can be rolled out to the public.
Officials say the vaccine, named Arexvy by the manufacturer GSK, is a major breakthrough that will save many lives. BBC News
See also:
- FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine US Food and Drug Administration
- FDA approves first-ever vaccine for RSV virus which kills 10,000 Americans every year The Daily Mail
- ‘A good day’: FDA approves world’s first RSV vaccine Nature
Is this anti-vaccine conspiracy theorist the next Alex Jones?
Is this anti-vaccine conspiracy theorist the next Alex Jones? A film promoting an anti-vaccine conspiracy theory has been accused of helping to drive the harassment of bereaved families. In a rare interview with the BBC, the man behind it says he is "happy" about its influence - and believes the people responsible for Covid vaccinations should be executed. BBC News
Regularly using internet LOWERS risk of dementia by 50% in middle age, study claims
Regularly using internet LOWERS risk of dementia by 50% in middle age, study claims We're often told of the dangers of too much screen time, but a study suggests regularly using the internet may slash the risk of dementia.
Researchers at New York University tracked 18,000 adults aged between 50 and 65 for about eight years.
They were asked at the start of the study and then again every two years if they 'regularly' used the web to send emails, shop, browse or book vacations.
Those who answered 'yes' most of the time had a 50 percent lower risk of being diagnosed with all forms of dementia compared to those who normally said 'no' by the end of the research. The Daily Mail
See also:
- Internet usage and the prospective risk of dementia: A population-based cohort study (open access) Journal of the American Geriatrics Society
Launch of a jab to help weight loss has been paused - because suppliers fear demand will be too high
Launch of a jab to help weight loss has been paused - because suppliers fear demand will be too high The launch of a 'game-changing' jab to help weight loss has been paused because suppliers fear demand will be too high.
Weight loss services in Britain had expected Wegovy to hit shelves this week but have now been told there might be an indefinite delay.
The weekly jabs were approved by the NHS and the National Institute of Health and Clinical Excellence (Nice) had recommended the drug to tens of thousands of overweight Brits. The Daily Mail
See also:
Subscribe to:
Posts (Atom)